Antares Pharma (NASDAQ:ATRS) Lowered to “Neutral” at HC Wainwright

Antares Pharma (NASDAQ:ATRS – Get Rating) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, The Fly reports.

Several other equities research analysts have also weighed in on the stock. Raymond James lowered shares of Antares Pharma from a “strong-buy” rating to a “market perform” rating in a report on Thursday. StockNews.com raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Tuesday. Truist Financial lowered shares of Antares Pharma from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Zacks Investment Research raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a report on Monday, March 7th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Shares of Antares Pharma stock opened at $5.58 on Thursday. The firm has a market capitalization of $949.21 million, a PE ratio of 20.67 and a beta of 1.52. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.96 and a quick ratio of 2.76. The company’s fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.60. Antares Pharma has a 52-week low of $3.11 and a 52-week high of $5.59.

Antares Pharma (NASDAQ:ATRS – Get Rating) last announced its quarterly earnings results on Thursday, March 3rd. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.01. The firm had revenue of $48.73 million for the quarter, compared to analyst estimates of $46.25 million. Antares Pharma had a net margin of 25.16% and a return on equity of 12.33%. During the same quarter in the previous year, the firm posted $0.03 EPS. Analysts predict that Antares Pharma will post 0.08 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of ATRS. Amundi Pioneer Asset Management Inc. acquired a new position in Antares Pharma during the 1st quarter worth about $730,000. Wells Fargo & Company MN lifted its position in Antares Pharma by 62.8% during the 2nd quarter. Wells Fargo & Company MN now owns 550,708 shares of the specialty pharmaceutical company’s stock worth $2,402,000 after buying an additional 212,405 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in Antares Pharma by 78.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 129,473 shares of the specialty pharmaceutical company’s stock worth $565,000 after buying an additional 56,842 shares in the last quarter. WINTON GROUP Ltd acquired a new position in Antares Pharma during the 3rd quarter worth about $46,000. Finally, SG Americas Securities LLC lifted its position in Antares Pharma by 79.9% during the 3rd quarter. SG Americas Securities LLC now owns 137,318 shares of the specialty pharmaceutical company’s stock worth $500,000 after buying an additional 60,988 shares in the last quarter. Institutional investors and hedge funds own 48.63% of the company’s stock.

Antares Pharma Company Profile (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Further Reading